Investors
A national champion, preparing to go public
Satoria Pharma combines market leadership, structural demand and a proprietary cost advantage — with an IPO planned to fund the next phase of regional growth.
0M+
Annual production (2026)
0%
Share of national infusion needs
0M
Capacity target by 2028
0
Export markets in development
Investment Thesis
Why Satoria Pharma
Market leadership
Indonesia's largest infusion manufacturer, supplying approximately half of national infusion demand from a single, modern site.
Structural demand
Infusion therapy is non-discretionary hospital consumption in the world's fourth most populous nation — with government policy favoring domestic supply.
Cost advantage
Proprietary ISBM production delivers 40–50% cost efficiency versus conventional technology, protecting margins and enabling export competitiveness.
Visible growth runway
Line 5 targets 400M bottles by 2028; export expansion into Vietnam, Cambodia and the Philippines is underway following first shipments in 2026.
Institutional enquiries welcome
For information regarding the planned public offering, partnership structures or facility due-diligence visits, contact our corporate team.
This page is provided for general information only and does not constitute an offer of securities. Figures reflect publicly reported company information and plans, which are subject to change.